Viking Therapeutics, Inc. cotiza a 28.51 USD y tiene una capitalización bursátil de $3.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase I…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.10 | $-1.37 | $-1.38 |
| Estimado | $-1.06 | $-1.21 | $-0.91 | $-0.90 |
| Sorpresa | — | +9.1% | -50.5% | -53.3% |
| Métrica | VKTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -56.3% | -40.4% | -15.9% |
| ROA | -50.3% | -32.0% | -18.2% |
| Current Ratio | 9.33 | 2.84 | +6.49 |
| Debt / Equity | — | 0.28 | — |